Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Blachly

Showing results (101-110 of 144) with videos related to

Pageof 15
Sort By:
Leukemia|January 13, 2025
Prognostic, biological, and structural implications of FLT3-JMD point mutations in acute myeloid leukemia: an analysis of Alliance studiesNadeen Anabtawi, Deedra Nicolet, Najla Alotaibi, et al.
Leukemia|February 24, 2023
Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance studyKrzysztof Mrózek, Jessica Kohlschmidt, James S Blachly, et al.
Leukemia|November 16, 2016
Mutations in the CCND1 and CCND2 genes are frequent events in adult patients with t(8;21)(q22;q22) acute myeloid leukemiaA-K Eisfeld, J Kohlschmidt, S Schwind, et al.
Journal of Hematology & Oncology|June 24, 2021
A precision medicine classification for treatment of acute myeloid leukemia in older patientsAlice S Mims, Jessica Kohlschmidt, Uma Borate, et al.
Haematologica|March 24, 2018
A novel regimen for relapsed/refractory adult acute myeloid leukemia using a <i>KMT2A</i> partial tandem duplication targeted therapy: results of phase 1 study NCI 8485Alice S Mims, Anjali Mishra, Shelley Orwick, et al.
Genome Research|March 12, 2021
DNA methylation epitypes highlight underlying developmental and disease pathways in acute myeloid leukemiaBrian Giacopelli, Min Wang, Ada Cleary, et al.
JCI Insight|December 3, 2020
TP-0903 is active in models of drug-resistant acute myeloid leukemiaJae Yoon Jeon, Daelynn R Buelow, Dominique A Garrison, et al.
Blood|August 23, 2021
Insertion of atypical glycans into the tumor antigen-binding site identifies DLBCLs with distinct origin and behaviorGiorgia Chiodin, Joel D Allen, Dean J Bryant, et al.
Leukemia|November 14, 2022
VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemiaSteven Sher, Ethan Whipp, Janek Walker, et al.
Experimental Hematology & Oncology|March 4, 2024
The multi-CDK inhibitor dinaciclib reverses bromo- and extra-terminal domain (BET) inhibitor resistance in acute myeloid leukemia via inhibition of Wnt/β-catenin signalingAlexander R Marr, Madeline Halpin, Dominique L Corbin, et al.
Pageof 15

Showing results (101-110 of 144) with videos related to

Sort By:
Pageof 15
Leukemia|January 13, 2025
Prognostic, biological, and structural implications of FLT3-JMD point mutations in acute myeloid leukemia: an analysis of Alliance studiesNadeen Anabtawi, Deedra Nicolet, Najla Alotaibi, et al.
Leukemia|February 24, 2023
Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance studyKrzysztof Mrózek, Jessica Kohlschmidt, James S Blachly, et al.
Leukemia|November 16, 2016
Mutations in the CCND1 and CCND2 genes are frequent events in adult patients with t(8;21)(q22;q22) acute myeloid leukemiaA-K Eisfeld, J Kohlschmidt, S Schwind, et al.
Journal of Hematology & Oncology|June 24, 2021
A precision medicine classification for treatment of acute myeloid leukemia in older patientsAlice S Mims, Jessica Kohlschmidt, Uma Borate, et al.
Haematologica|March 24, 2018
A novel regimen for relapsed/refractory adult acute myeloid leukemia using a <i>KMT2A</i> partial tandem duplication targeted therapy: results of phase 1 study NCI 8485Alice S Mims, Anjali Mishra, Shelley Orwick, et al.
Genome Research|March 12, 2021
DNA methylation epitypes highlight underlying developmental and disease pathways in acute myeloid leukemiaBrian Giacopelli, Min Wang, Ada Cleary, et al.
JCI Insight|December 3, 2020
TP-0903 is active in models of drug-resistant acute myeloid leukemiaJae Yoon Jeon, Daelynn R Buelow, Dominique A Garrison, et al.
Blood|August 23, 2021
Insertion of atypical glycans into the tumor antigen-binding site identifies DLBCLs with distinct origin and behaviorGiorgia Chiodin, Joel D Allen, Dean J Bryant, et al.
Leukemia|November 14, 2022
VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemiaSteven Sher, Ethan Whipp, Janek Walker, et al.
Experimental Hematology & Oncology|March 4, 2024
The multi-CDK inhibitor dinaciclib reverses bromo- and extra-terminal domain (BET) inhibitor resistance in acute myeloid leukemia via inhibition of Wnt/β-catenin signalingAlexander R Marr, Madeline Halpin, Dominique L Corbin, et al.
Pageof 15